Quarterly ResultJun 10, 2026, 04:22 PM
Aethlon Medical FY2026 Net Loss $7.2M; Oncology Study Enters Final Cohort
AI Summary
Aethlon Medical, Inc. announced its financial results for the fiscal year ended March 31, 2026, reporting a reduced net loss of $7.2 million compared to $13.4 million in the prior year, alongside a 21.9% decrease in operating expenses to $7.3 million. Key business updates include advancing their Australian oncology study into the final dosing cohort and strengthening the Hemopurifier intellectual property portfolio with new patents for coronavirus-related conditions. The company also reported $5.0 million in cash and cash equivalents as of March 31, 2026.
Key Highlights
- Aethlon Medical reported a net loss of $7.2 million for FY2026, a decrease from $13.4 million in FY2025.
- Operating expenses decreased by 21.9% to $7.3 million in FY2026 from $9.3 million in FY2025.
- The Australian oncology study advanced to the third and final dosing cohort.
- New patents were issued in the US and Europe for Hemopurifier applications in coronavirus-related conditions.
- Preclinical research is evaluating Hemopurifier for rheumatoid arthritis and chronic kidney disease.
- Cash and cash equivalents were $5.0 million as of March 31, 2026.
- The company raised approximately $1.85 million in net proceeds through its at-the-market program post-fiscal year-end.
Price Impact
More from AEMD